SEC Form 4 · accession 0001827672-26-000009
Tarsus Pharmaceuticals, Inc. · TARS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bobak R. Azamian
Officer — President/CEO and Board Chair · Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 4:09 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001819790
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jun 17, 2026 | S | 4,582 | $61.24 | D | 853,409 | I | By the Bobak Azamian Living Trust established April 16, 2018 |
| Common StockF4,F3 | Jun 17, 2026 | S | 5,418 | $61.81 | D | 847,991 | I | By the Bobak Azamian Living Trust established April 16, 2018 |
| Common Stock | holding | — | — | — | 33,421 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
- F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $60.51 to $61.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
- F4The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $61.52 to $62.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.